Lineage Cell Therapeutics, Inc. business relationships

Companies named in Lineage Cell Therapeutics, Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name Lineage Cell Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 4.7 / 10
AI naming: 5 / 100
Agent readiness: 20 / 100
AI adoption: 0 / 100

Named in Lineage Cell Therapeutics, Inc.’s annual report 8

Roche GroupCustomer7.7
“Agreement, and (ii) up to 50% of all royalty payments (subject to a maximum payment of 5% of net sales of products) Lineage receives from Roche under the Roche Agreement.” SEC filing
Roche GroupLicensee7.7
“Pursuant to the Roche Agreement, we have licensed these patent rights to Roche to further develop and commercialize RPE cell therapies, including OpRegen (see "-Collaborations-Roche Collaboration Agreement" above).” SEC filing
Roche GroupLicensor7.7
“Achieved first milestone available under our collaboration and license agreement with Roche and Genentech based on manufacturing and clinical advancements to the OpRegen (RG6501) program.” SEC filing
Roche GroupPartner7.7
“Pursuant to the Roche Agreement, we have licensed these patent rights to Roche to further develop and commercialize RPE cell therapies, including OpRegen (see "-Collaborations-Roche Collaboration Agreement" above).” SEC filing
Genentech, IncLicensor4.7
“Achieved first milestone available under our collaboration and license agreement with Roche and Genentech based on manufacturing and clinical advancements to the OpRegen (RG6501) program.” SEC filing
Immunomic Therapeutics, Inc.Licensor4.7
“...7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.” SEC filing
Genentech, IncPartner4.7
“OpRegen is currently being evaluated by our partners Roche and Genentech in a Phase 2a multicenter clinical trial in patients with GA secondary to dry-AMD, the "GAlette" study, which is currently enrolling up to 60 patients at 17 clinical sites across the U.S. and Israel.” SEC filing
Immunomic Therapeutics, Inc.Partner4.7
“Further, Lineage notified Immunomic Therapeutics, Inc. ("ITI") of the termination of the collaboration agreement that Lineage had entered into with ITI in April 2021 (the "ITI Agreement") in accordance with its terms.” SEC filing

Companies whose annual reports name Lineage Cell Therapeutics, Inc. 1

Ocugen, Inc. (OCGN)names it as partner5.4
“Hoffmann-La Roche AG ("Roche AG"), Kiora Pharmaceuticals, Inc., Genentech, Inc. in partnership with Lineage Cell Therapeutics, Inc., and Luxturna, the product developed by Spark Therapeutics, Inc. and marketed by Roche AG, is currently the only gene therapy approved to treat IRDs in the United State...” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.